F8 and hemophilia A: When iqPCR was utilized in a clinical study that administered up to 6E+13 vg/kg of AAV5-FVIII-SQ gene therapy to hemophilia A participants, intact vector capsids were observed in plasma and semen but steadily decreased to undetectable levels in all tested participants by week 9.